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Risk stratification, prognostication and longitudinal monitoring of therapeutic 
efficacy in lung cancer patients remains highly challenging. It is imperative to 
establish robust surrogate biomarkers for identifying eligible patients, predicting 
and effectively monitoring clinical response as well as timely detecting emerging 
resistance to therapeutic regimens. Circulating tumor biomarkers, analyzed by 
liquid biopsy, are primarily composed of nucleic acid-based circulating tumor DNA 
(ctDNA) and an aneuploid cell-based category of circulating tumor cells (CTCs) 
and circulating tumor-derived endothelial cells (CTECs). Unlike ctDNA, cancer 
cells are the origin of all categories of various tumor biomarkers. Involvement of 
aneuploid CTCs and CTECs in tumorigenesis, neoangiogenesis, tumor progres-
sion, cancer metastasis and post-therapeutic recurrence has been substantially 
investigated. Both CTCs and CTECs possessing an active interplay and crosstalk 
constitute a unique category of cellular circulating tumor biomarkers. These cells 
concurrently harbor the intact cancer-related genetic signatures and full tumor 
marker expression profiles in sync with disease progression and therapeutic pro-
cess. Recent progress in clinical implementation of non-invasive liquid biopsy has 
made it feasible to frequently carry out ctDNA analysis and unbiased detection of a 
full spectrum of non-hematologic circulating rare cells including CTCs and CTECs 
in lung cancer patients, regardless of variation in heterogeneous cell size and cancer 
cell surface anchor protein expression. In situ phenotypic and karyotypic compre-
hensive characterization of aneuploid CTCs and CTECs, in combination with single 
cell-based genotyping and improved ctDNA analyses, will facilitate and benefit 
multidisciplinary management of lung cancer.
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1. Introduction
Recent progress in multidisciplinary management of advanced lung cancer has 
triggered enthusiasm in investigating both prognostic roles of tumor microenviron-
ment (TME) and clinical utilities of liquid biopsy in lung cancer patients [1, 2]. 
How the tumor-reprogrammed lung TME promotes primary tumor progression 
and cancer metastasis remains to be further elucidated [1].
Aberrant stromal and infiltrated immune cells, sustained neovascularization, 
as well as dysfunctional neoangiogenic vasculatures in solid tumors all contribute 
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towards constituting an immunosuppressive TME suitable for cancer cell growth 
and metastasis [3]. Tumor-derived endothelial cells (TECs) participate in making 
up the lining of neoangiogenic vasculatures in the TME and accelerating tumor 
progression [4, 5]. Following their shedding into peripheral blood, CD31− cancer 
cells and CD31+ TECs turn into circulating tumor cells (CTCs) [6] and circulating 
tumor-derived endothelial cells (CTECs) [7, 8], respectively. Beyond peripheral 
blood, tumor cells and TECs may also disseminate into body fluid including bone 
marrow (BM), malignant pleural effusion (MPE), ascites and cerebrospinal 
fluid (CSF), etc. These cells are respectively termed as disseminated tumor 
cells (DTCs) [9] and disseminated tumor-derived endothelial cells (DTECs). 
The non-hematologic circulating rare cells, consisting of CTCs, CTECs, DTCs 
and DTECs, possess the malignancy hallmark of aneuploidy [10–14] and play a 
fundamental role in tumorigenesis, neoangiogenesis, tumor progression, cancer 
metastasis and relapse [7, 13].
Liquid biopsy provides applicable and convenient choices for analyzing 
tumor-derived cells and molecules in cancer patients’ circulation system [15], 
which is particularly adequate for lung cancer as it does not require an invasive 
and harmful procedure to perform a conventional pathological biopsy on the 
malignant lesion in lung. Liquid biopsy utilizes non-invasive approaches to reveal 
the molecular landscape of neoplasm in real time and facilitate management of 
lung cancer throughout treatment process, from identifying eligible patients, 
dynamically monitoring therapeutic efficacy to detecting minimal residual 
disease and emerging resistance [16] with respect to guiding personalized  
precision therapy [2].
Being as a category of liquid biopsy technologies, analysis of tumor cell 
genome-derived circulating tumor DNA (ctDNA) has been applied to assist 
management of advanced stage lung cancer [2, 17]. The cell-free biomarker 
ctDNA measurements show rapid response to administration of therapeutic 
agents. Recent advance in molecular genotyping in terms of identifying genetic 
mutations in ctDNA has successfully guided therapies targeting mutant EGFR 
or the EML4-ALK rearrangement in lung cancer patients [18, 19]. However, the 
specificity and sensitivity of ctDNA assay remain challenging [20, 21]. Compared 
to ctDNA, CTC has presented its unique advantage in terms of being as an 
effective response measure of prolonged survival for metastatic cancer patients 
in multiple clinical studies [22]. It has been realized that aneuploid circulating 
rare cells constitute a unique category of viable cell-based cellular circulating 
tumor biomarkers. Those cellular circulating tumor biomarkers contain intact 
genetic signatures and full protein expression profiles along with tumor progres-
sion and throughout clinical treatment process [7, 13]. The clinical relevance of 
aneuploid circulating rare cells in the context of tumor angiogenesis [23], cancer 
metastases and prognosis [6, 9] was described elsewhere [9, 24]. Detection of 
CTCs and CTECs has been clinically applied to prognosticate lung cancer patients 
[22], evaluate or monitor therapeutic efficacy in both cancer patients [25–27] and 
patient- or CTC-derived xenograft tumor mouse model (PDX, CDX) [28–31]. 
Moreover, examination of CTCs and CTECs has been successfully utilized to 
timely detect emerging therapeutic resistance [32–36] as well as postsurgical 
cancer relapse [37, 38]. Overall, availability of analysis of circulating rare cells 
has brought extraordinary depth by allowing feasible frequent examination 
of the whole intact target cells and their molecular contents including cancer-
related DNA, RNA and tumor marker proteins [21]. Other liquid biopsy-relevant 
genotyping strategies conducted on circulating exosomes, microRNA, mRNA, 
metabolites and tumor-educated platelets are immature and remain to be further 
optimized and clinically validated [2, 17].
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Categorization and clinical utilities of tumor liquid biopsy, primarily composed 
of nucleic acid-based and cell-based circulating tumor biomarker analyses, are 
depicted in Figure 1.
2. Hypoxic tumor microenvironment in lung cancer
The lung TME is a complex, dynamic system comprised of tangled interac-
tions among carcinoma cells and their surrounding cells in a hypoxic environment 
[39, 40]. Aside from non-cellular compositions of cytokine and extracellular 
matrix, the cellular components of the lung cancer TME consist of undifferenti-
ated cancer stem cells (CSCs) [41] and their differentiated progeny tumor cells 
possessing either intrinsic or induced plasticity [42]. In addition, a variety of cells 
other than neoplastic cells also localize in the TME, which, able to foster both 
tumor growth and dissemination, are composed of stromal cells and non-stromal 
immune cells. Tumor-associated stromal cells consist of cancer-associated fibro-
blasts (CAFs), pericytes, adipocytes and endothelial cells (ECs) that make up the 
lining of tumor vasculature. The innate immune cells in the TME encompass den-
dritic cells, monocytes, macrophages and lymphocytes. The major components 
of lymphocytes in the TME are tumor-infiltrating T cells which are recognized as 
a hallmark of cancer [43]. Among different subtypes of T cells in the lung TME, 
CD3+/CD8+ cytotoxic T cells and CD3+/CD4+/CD25+ regulatory T cells (Tregs) 
are the most representative subpopulations. Cytotoxic T cells exhibit anti-tumor 
activity which is negatively regulated by the FOXP3+ immune-suppressive Tregs 
[44]. Alike prognostic factors of immune cells in the lung TME, the FOXP3+ Tregs 
correlate with poor prognosis [44] and early recurrence, particularly in node-
negative NSCLC patients [45].
Hypoxia, a common phenomenon in malignant neoplasm, leads to acquisition 
of epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal 
transition (EndoMT) phenotypic plasticity by epithelial cancer cells and endothe-
lial cells, respectively. Hypoxia-inducible factor (HIF) pathway is the most distinc-
tive intracellular signaling event that triggers and regulates EMT and EndoMT [7]. 
HIF pathway is activated in the hypoxic lung TME, resulting in nuclear transloca-
tion of HIF-1α and subsequent heterodimerization with HIF-1β in the nucleus [46]. 
HIF-1α/β heterodimers subsequently interact with NFκB to promote a series of 
downstream signaling cascades. Hypoxia is, therefore, the vital inducer of EMT and 
Figure 1. 
Categorization of tumor liquid biopsy. Various cellular and molecular approaches are applied in the  
non-invasive tumor liquid biopsy to detect nucleic acid-based and cell-based circulating tumor biomarkers.
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EndoMT [47, 48] which fundamentally constitute the intracellular central hub of 
tumor neovascularization and cancer metastasis [7].
In the hypoxic TME, active crosstalk among carcinoma cells and their associated 
stromal cells accelerates lung cancer development by promoting tumor expansion, 
invasion and disease progression [49, 50]. The lung hypoxic TME thereby signifi-
cantly impacts both malignant tumor progression and treatment response. Impaired 
vascularity and hypoxia will lead to an increased metastasis potential and treatment 
resistance in lung cancer [39].
3. ctDNA
ctDNA is released from apoptotic or necrotic cancer cells either in the TME 
of primary/metastatic lesions or in peripheral circulation. ctDNA levels correlate 
with tumor burden and response to therapy in NSCLC patients [51, 52]. In contrast 
to normal cells, neoplastic cells possess tumor-specific somatic alternations in 
the genome. Mutations harbored by ctDNA, including both point mutations and 
structural alternations (such as genome-wide copy number variations and rear-
rangements), correspond to that in primary tumors [21].
3.1 Clinical application of ctDNA
Following rapid evolvement of PCR and next generation sequencing (NGS)-based 
ctDNA analysis, its clinical application as a high-throughput diagnostic test has been 
facilitated in several areas. (i) Early detection of lung cancer: localized lung cancer at 
early stage sheds DNA into peripheral circulation and detection of methylated ctDNA 
may help diagnose early stage lung cancer [53]. (ii) Tumor genotyping to identify 
lung cancer patients eligible for mutation-targeted therapies: the most representative 
example is to examine sensitizing exon 19 deletions and the L858R mutation as well 
as the resistance mutation T790M in plasma ctDNA. All will guide administration 
of EGFR-Tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib 
to lung cancer patients [18]. (iii) Surrogates of therapeutic efficacy: ctDNA dynam-
ics is able to predict benefit of immunotherapy [54] and may also correlate with 
chemoradiation efficacy in lung cancer patients [55]. (iv) Identification of localized 
lung cancer at high risk of disease relapse: compared to conventional histopathologi-
cal criteria in identifying post-therapeutic localized lung cancer patients suitable 
for personalized adjuvant therapeutic setting, cancer personalized profiling by deep 
sequencing (CAPP-seq) ctDNA analysis is able to detect post-surgical minimal or 
molecular residual disease (MRD), thereby identifying patients bearing the lowest 
disease burden eligible for adjuvant therapy [21, 56]. (v) Early detection of lung 
cancer relapse: whole genome analysis of ctDNA may directly identify tumor-
derived structural alternations comprised of chromosomal copy number changes 
and rearrangements, including specific amplification of cancer driver genes (ERBB2, 
CDK6, etc.) that correlate with cancer recurrence [57]. In addition, phylogenetic 
ctDNA profiling was also reported to enable detection of recurrent NSCLC at early 
stage [58].
3.2 Limitations and improvement of ctDNA analysis
Advances in next generation DNA sequencing technologies have promoted 
clinical application of ctDNA as a tool to facilitate management of lung cancer, 
such as earlier detection and improvement of therapeutic outcomes by enabling 
early intervention, etc. However, limitations of ctDNA have recently attracted 
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increasing attention. Cancer-related genetic contents carried by fractured ctDNA is 
limited due to its 90–150 base pairs of small fragments [2]. Moreover, in carcinoma 
patients, little amount of cancer-related ctDNA co-exist with much larger amount 
of cancer-irrelevant cell free DNA (cfDNA) shed from normal cells in peripheral 
blood [2, 17]. This raises notable concerns regarding the specificity and sensitivity 
of ctDNA analysis [20, 21], particularly for low-frequency mutation detection in 
early stage NSCLC patients [59]. Such concern has been recently further reen-
forced by copious data analyses co-performed by the American Society of Clinical 
Oncology (ASCO) and the College of American Pathologists (CAP), indicating that 
clinical utility and validity of ctDNA in early-stage cancer detection, treatment 
monitoring, or residual disease detection in a variety of cancer patient are still 
vague and inconclusive [60]. Extensive clinical studies, performed by the improved 
technologies with higher sensitivity and specificity, will further validate and reveal 
clinical utilities of ctDNA.
4. Aneuploid CTCs and CTECs
Almost all different types of tumor biomarkers originate from neoplastic cells. 
CTCs and CTECs dynamically comprise integral molecular landscape of both 
cancer-related genetic variations and tumor marker expression along with tumor 
progression and clinical treatment process.
4.1 Aneuploidy in malignant cancer cells
Aneuploidy refers to either a gain or loss of chromosomes in a cell. Unlike con-
stitutional aneuploidy, somatic aneuploidy is the most common feature of human 
carcinomas [11, 12]. In particular, aneuploid chromosome 8 (Chr 8) was observed 
in neoplastic cells of almost all solid tumors, including lung cancer [61].
Aneuploidy is a cellular transformation-related dynamic chromosome mutation 
event regulated by cell fusion and a number of mitotic genes [7, 62]. Mutations 
of those mitotic genes were identified in cancer cells, implicating such mutation 
in induction of mis-chromosome segregated aneuploidy in neoplastic cells [63]. 
Aberrant ploidy of extra chromosomes in cancer cells was found to relevant to 
genomic instability [64]. In addition, gain or deletion of hundreds of genes brought 
by aneuploidy in carcinoma cells results in profound varieties of phenotypes, 
which further drives cancer development, evolution, heterogeneity, lethal progres-
sion, drug resistance and therapy failure [14, 65]. Of extreme importance was the 
discovery that the degree of aneuploidy is proportional to the grade of malignancy 
and genetic instability of neoplasm [66, 67], showing that the higher the degree of 
aneuploidy, the higher the frequency of KRAS and TP53 mutations, and the higher 
the malignancy grade of cancer cells [62, 67, 68].
4.2 Cytogenetic abnormalities in CTCs and CTECs
In the lung cancer TME, alike aneuploid neoplastic cells, a majority of ECs in 
tumor vasculature are aneuploid TECs [69] that could be derived from either endo-
thelialization of malignant lung cancer cells or cancerization of stromal ECs [7, 70]. 
Abnormal neovasculature composed of TECs possesses loosened junctions between 
ECs, resulting in an increased vascular permeability and transendothelial intravasa-
tion as well as extravasation during tumor metastasis. Aneuploid TECs, harboring 
dual-properties of endothelial vascularization ability and cancerous malignancy 
[71], were reported to contribute to tumor progression [5]. Following shedding into 
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blood, both CTCs and CTECs adopt molecular properties from their parental cells 
in the TME of primary lesion, including cytogenetic abnormalities of aneuploidy. 
Each subcategory of those aneuploid circulating rare cells correlate with distinct 
clinical endpoints, such as targeted distant cancer metastasis [72, 73] and resistance 
to chemo- [33, 34] or immunotherapy [36].
5.  Co-detection, comprehensive characterization and clinical value of 
diverse subtypes of lung cancer CTCs and CTECs
5.1 Conventional strategies to detect lung cancer CTCs
Several strategies were applied to attempt to detect CTCs in lung cancer patients 
[74]. CTC surface anchor protein (such as CD326 EpCAM)-dependent isolation 
(e.g. CellSearch) and cell size-exclusion filtration to enrich large cell size CTCs 
(>WBC size) are the most representative conventional approaches. However, it 
has been realized that clinically relevant small cell size CTCs (≤WBC size), such 
as mesenchymal CTCs [75], are lost throughout the filtered depletion of WBCs, 
raising non-negligible concerns with respect to specificity and sensitivity for 
cell filtration strategy [76, 77], particularly for lung cancer CTC detection [78]. 
CellSearch technology relies on positive expression of EpCAM and cytokeratin 
(CK) for isolation and identification, respectively. This method, restricted to 
both EpCAM and CK double-positive cells, is able to effectively detect CTCs shed 
from some particular types of solid tumors expressing abundant epithelial marker 
EpCAM, such as colon, breast and prostate cancers [79]. However, a majority 
of CTCs in various carcinoma patients exhibit a highly dynamic distribution of 
EpCAM during cancer progression and metastasis [80, 81]. Additionally, expression 
of EpCAM and CK is down-regulated during EMT in the process of CTC formation 
[81, 82]. Furthermore, most lung cancer CTCs exhibit either low or non-expression 
of EpCAM [83, 84]. Those inherited cell biological “hurdles” inevitably lead to 
a false negative detection of the “uncapturable” and/or “invisible” lung CTCs by 
the conventional approach [85]. It is therefore necessary to develop an alternative 
strategy, beyond restriction to EpCAM and CK double positive expression, to 
effectively isolate, identify, comprehensively characterize and classify a variety of 
highly heterogeneous aneuploid circulating rare cells in lung cancer patients.
5.2  In situ phenotypic and karyotypic characterization of aneuploid CTCs and 
CTECs by iFISH
Aside from respectively addressing nucleic acid, tumor marker proteins, or cell 
morphology alone, a comprehensive strategy integrating subtraction enrichment 
(SE) and immunostaining-fluorescence in situ hybridization (SE-iFISH) has been 
developed to effectively enrich and identify heterogeneously sized circulating rare 
cells [8, 61]. Following non-hypotonic removal of RBCs, subtraction enrichment is 
able to effectively enrich circulating rare cells in varieties of cancer patients including 
NSCLC and small cell lung cancer (SCLC) [86], regardless of cell size variation and 
the target cell surface anchor protein expression. Following efficient enrichment, 
iFISH co-detects tumor marker expression and chromosome aneuploidy in enriched 
non-hematologic circulating rare cells (CRCs) [61]. Besides, iFISH is also able to 
detect aneuploid hematologic rare cells derived from lymphoma and myeloma 
(CD45+, aneuploid in Chr 12). As depicted in Figure 2, the most representative 
populations of the primary entity of non-hematologic aneuploid circulating rare 
cells, identified by iFISH, are CTCs/CTECs in peripheral blood and DTCs/DTECs in 
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body fluid. Under hypoxic conditions, some CD31− tumor cells (TCs) could transdif-
ferentiate into CD31+ TECs, both in vivo and in vitro [7, 87, 88].
Based upon the degree of aneuploidy, tumor marker protein expression and cell 
morphology (large, small, cluster or microemboli), each category of circulating 
rare cells can be classified into diverse subtypes. Each subtype of cells respectively 
possesses distinct clinical values.
5.3 Clinical significance of CTCs and CTECs in lung cancer
5.3.1 Quantification
Clinical utilities of detecting CTCs and CTECs in management of NSCLC and 
SCLC have been investigated along the axis of “early diagnosis–treatment–relapse” 
[89]. Though low-dose CT (LDCT) screening was reported to reduce lung cancer 
mortality in low-risk populations [90, 91], its extensive application is limited due to 
relatively low sensitivity in high-risk populations [17, 90], unavailability of frequent 
re-examinations within a short period as well as socio-economic affordability. As a 
diagnostic marker of lung cancer, non-invasive and periodic detection of CTCs and 
CTECs may provide a compensatory choice to allow an effective early diagnosis of lung 
cancer [17, 92–94]. Multiple studies indicated that lung cancer CTCs could be detected 
several months prior to radiographic appearance of the primary lesion [74, 95].
With respect to diagnosed lung cancer patients, the quantity of CTCs was found 
to correlate with patients’ pathological staging as well as amount of cytokeratin 
19-derived Cyfra 21–1 in plasma [86, 96]. CTC is a risk stratification parameter 
for NSCLC in terms of distant metastasis [73, 97]. Prognostic values of CTCs in 
therapeutic lung cancer patients were published elsewhere [86, 98], indicating 
that baseline lung CTC counts were associated with patients’ poor prognosis and 
response to treatment [99]. Compared to evaluation of therapeutic efficacy per-
formed by CT scanning and RECIST criteria, quantitative change in CTCs occurs 
ahead of conventional medical imaging examination [86, 100], suggesting that 
cellular response to therapeutic regimens is more sensitive than observable size 
variation in imaged tumor mass.
Figure 2. 
Categorization of aneuploid circulating rare cells comprehensively identified and characterized by iFISH. 
Aneuploid circulating rare cells (CRCs) are classified into hematologic and non-hematologic categories. The 
former class is composed of lymphoma, myeloma, etc. which are aneuploid in chromosome 12. The  
non-hematologic category consists of CD31− CTCs and CD31+ CTECs in blood, DTCs as well as disseminated 
TECs (DTECs) in body fluid (bone marrow, malignant pleural effusion, ascites, cerebrospinal fluid, etc.). 
The aneuploid non-hematologic CRCs, either expressing tumor markers or not, constitute a unique category 
of cell-based cellular circulating tumor biomarkers. In the hypoxic environment, some CD31− tumor cells 
(TCs) may transdifferentiate into CD31+ TECs either in vivo or in vitro.
Lung Cancer - Modern Multidisciplinary Management
8
Close attention has been recently focused on whether surgical resection may 
promote a quantitative increase in lung cancer CTCs. Although a study performed 
by the EpCAM-dependent strategy indicated that surgical approaches did not 
impact CTC quantity [101], the conclusion was uncertain due to the reality that the 
applied technology was biased in restricting to CK and EpCAM double-positive 
CTCs which account for only a very small proportion of overall lung CTCs. 
Nonetheless, several studies performed by others using different technical plat-
forms indicated that surgical manipulation indeed increased CTC quantity either 
in pulmonary venous (PV) blood during surgery [102, 103] or in post-surgical 
patients’ peripheral blood [104]. Increased CTCs in PV were reported to associate 
with patients’ poor prognosis [103, 105]. Similar to association of post-surgical 
hepatocellular carcinoma (HCC) CTCs with cancer relapse [38], detection of CTCs 
in PV during operation or in post-surgical peripheral blood also enables early 
detection of lung cancer recurrence, particularly in the post-resected lung cancer 
patients [37, 106–108].
5.3.2 Molecular characterization
In addition to enumerating cell number alone, molecular characterization of 
DNA, RNA, chromosomes and proteins in circulating rare cells has been carried out 
to investigate the clinical relevance of molecular landscape in diverse subcategories 
of lung CTCs and CTECs [36, 93, 109].
Tumor-associated DNA copy number aberrations (CNAs) profiling illustrated 
distinctive genetic features in chemosensitive and chemorefractory SCLC CTCs 
[110], that will be beneficial to patients’ personalized precision therapy. Besides 
DNA, the quantity of several tumor markers’ mRNA, such as CEA mRNA in both 
pre- and post-surgical NSCLC patients, may serve as an independent prognosticator 
for poor prognosis [111].
Compared to a significant reduction in risk of mortality in post-surgical 
NSCLC patients who had near-diploid tumors [68, 112], subjects possessing aneu-
ploidy in lung cancer cells exhibited a significant increase in risk of death [112]. 
Recent studies demonstrated that aneuploidy plays a critical role in chemoresis-
tance in gastric cancer patients [33, 34] as well as in metastatic “patient-derived 
xenograft tumor mouse models” (mPDX) exhibiting primary gastric cancer 
metastasizing to lung [30]. For instance, gastric CTCs with trisomy 8 were found 
to possess intrinsic chemoresistance, whereas multiploid (≥pentasomy 8) CTCs 
displayed acquired resistance to cisplatin. It is logical to speculate that aneuploid 
lung cancer CTCs may share the similar property of aneuploidy-related therapeu-
tic resistance.
Efficient identification of lung cancer patients eligible for targeted therapies 
remains a challenging topic. Compared to conventional detection of ALK rear-
rangement on biopsy specimen with respect to identifying subjects for crizotinib 
treatment, detection performed on CTCs to examine ALK rearrangement provides 
a better alternative in terms of rapidity and repeatability [13, 113, 114]. Targeted 
therapy on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(gefitinib and erlotinib TKIs) has been profoundly applied to eligible NSCLC 
patients. Single cell-based analysis of genetic abnormalities, such as exon 19 
deletion/EGFR L858R TKI-sensitizing mutation [115] and T790M TKI-resistance 
mutation in CTCs, could serves as an adequate alternative to identify eligible 
patients [116] and timely monitor emerging acquired therapeutic resistance to TKIs 
throughout therapy [117, 118]. Interestingly, compared to the 33% positive detection 
rate of EGFR L858R in ctDNA, 92% of the same cohort showed such mutation in 
their CTCs [117].
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Next-generation sequencing (NGS) successfully guided in vitro drug screen-
ings carried out on the cultured primary CTCs [119]. One study demonstrated 
that NGS performed on the cultured metastatic tumor cells which were enriched 
from cerebrospinal fluid in breast cancer patients led pinpointing of chemothera-
peutic agent palbociclib (the synthetic CDK4/6 inhibitor) upon identifying single 
nucleotide variant (SNV) in those cells [120]. A similar in vitro therapeutic drug 
screening strategy performed on 3D cultured CTCs was reported to help direct 
potent lung cancer precision therapy [121]. In addition to analyzing DNA muta-
tions in pooled CTCs, the single-cell based DNA [29] or RNA sequencing [31] 
performed on chemosensitive and chemoresistant CTC-derived xenografts (CDX) 
demonstrated that intratumoral heterogeneity (ITH), which was constituted of 
coexisting subpopulations of cancer cells with heterogeneous gene expression, 
led to the development of platinum-resistance in SCLC patients [29, 31]. A similar 
study performed by others on SCLC PDX and CDX confirmed that these models 
were able to capture the mutational landscape and functional traits from their 
primary donor tumors [28].
Aside from genetic and karyotypic characterization, phenotypic analysis of 
tumor marker protein expression in CTCs provides additional prognosticating 
value. For instance, EpCAM and Vimentin are the epithelial and mesenchymal 
markers of EMT and EndoMT, respectively [122, 123], both showing particular 
clinical outcomes in carcinoma patients. EpCAM+ CTCs and DTCs are able to lead 
oligometastasis to lung in breast carcinoma patients [72]. Moreover, CTCs express-
ing EpCAM correlate with poor prognosis in lung cancer patients [84]. Vimentin+ 
CTC is another independent prognosticator for poor prognosis and survival. 
Positive detection of Vimentin+ CTCs at baseline has been recently reported to 
associate with lung cancer’s hepatic metastasis and patients’ poor prognosis [73].
5.3.3 Clinical utilities of co-detection of CTCs and CTECs
Most efforts made on liquid biopsy have, so far, been primarily focusing on 
CTCs. In comparison with CTCs, the aneuploid CD31+ CTECs, harboring mixed 
properties of epithelium, endothelium, mesenchyme, aneuploidy, malignancy and 
mobility, are expected to perform an important role in tumorigenesis, progression, 
metastasis and neovascularization [7]. Since the existence of CTECs in cancer 
patients was reported for the first time [8], clinical values of CTECs in a variety of 
carcinoma patients have been illustrated [7, 36, 93, 124]. Compared to CTCs, lung 
cancer CTECs appear to be more relevant to therapeutic resistance and disease 
progression. Particularly, in NSCLC patients subjected to the checkpoint blockade 
immunotherapy (nivolumab), unlike nivolumab-sensitive PD-L1+ CTCs which 
revealed a quantitative decrease following treatment, the number of post-immuno-
therapeutic aneuploid PD-L1+ CTECs increased. Patients possessing post-immuno-
therapeutic aneuploid PD-L1+ CTECs showed a significantly shorter PFS compared 
to those without PD-L1+ CTECs [36]. Innovative attempts to therapeutically target 
CTEC-relevant EndoMT and aneuploidy will vitally impact aneuploid CTECs and 
ultimately improve lung cancer patients’ treatment efficacy [125, 126]. As a novel 
and mobile therapeutic target, elimination of CTECs in cancer patients is expected 
to promote an effective obstruction in cancer metastasis.
Detection and clinical values of advanced molecular characterization of lung 
cancer CTCs and CTECs are summarized in Table 1.
To maximize clinical values of CTCs and CTECs, it is ideal to co-characterize 
all three elements of nucleic acids, tumor marker protein expression and cellular 
morphology in target cells. Such three-in-one comprehensive co-detection and 
molecular characterization of aneuploid circulating rare cells will effectively and 
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efficiently assist modern multidisciplinary management of lung cancer with respect 
to early-stage screening, identification of eligible patients, selection and optimiza-
tion of therapeutic regimen, risk stratification, minimal residual disease detection, 
timely evaluation of therapeutic efficacy, monitoring treatment resistance and early 
detection of post-therapeutic recurrence.
6. Conclusions
Both aneuploid CD31+ CTECs and CD31− CTCs compose a unique pair of cellular 
circulating tumor biomarkers that have an active crosstalk and interplay in circulation, 
thus promoting lymphogenous and hematogenous cancer metastasis as well as disease 
progression. CTECs, bearing properties of malignancy, vascularization and mobility, 
serve as a significant, versatile player in tumor neovascularization and cancer metas-
tasis. Clinical implementation of advanced co-detection and comprehensive charac-
terization of all diverse subtypes of aneuploid CTCs and CTECs, in combination with 
single cell-based genetic signature profiling and improved ctDNA analysis will help 
improve and profit current and future cancer research and precision management of 
patients with a variety of carcinomas, including, but not limited to, lung cancer.
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Clinical values of lung cancer CTCs and CTECs References
Early diagnosis [17, 74, 92, 93, 95]
Pathological staging [86, 96]
Identification of eligible patients (TKIs, ALK crizotinib) [13, 114, 116]
In vitro therapeutic drug screening [120, 121]
Under treatment
Risk assessment for distant metastasis [73, 97]
Prognosis [72, 73, 84, 86, 98–100, 112]
Post-surgery (prognostic value) [102–105]
Timely monitoring therapeutic resistance [31, 36, 110, 117, 118]
Early detection of recurrence [37, 74, 106–108]
Advanced molecular characterization
Aneuploidy and ALK rearrangement [13, 112–114]
Co-detection of aneuploidy and tumor marker
expression in CTCs and CTECs (iFISH)
[8, 36, 61]
CTC-derived xenograft (CDX) [28, 29, 31]
Single cell-based DNA sequencing [28, 29, 110, 116, 118]
Single cell-based RNA sequencing [31]
Table 1. 
Clinical utilities of detecting lung cancer CTCs and CTECs.
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